News & Updates

Show Multimedia Only

1-day octreotide infusion not inferior to 5-day regimen for acute esophageal variceal bleeding

06 Sep 2026

The 1-day regimen of octreotide following a successful endoscopic band ligation demonstrates noninferiority to the standard 5-day regimen in preventing 5-day rebleeding, with no significant differences in the prevention of 6-week rebleeding and all-cause mortality, a study has shown.

1-day octreotide infusion not inferior to 5-day regimen for acute esophageal variceal bleeding

06 Sep 2026

Are PPIs necessary after endoscopic band ligation?

05 Sep 2026

Routine use of proton pump inhibitors (PPIs) after endoscopic band ligation (EBL) of esophageal varices in patients with cirrhosis lacks sufficient evidence, according to a systematic review and meta-analysis.

Are PPIs necessary after endoscopic band ligation?

05 Sep 2026

Vedolizumab, ustekinumab both safe, effective in biologic-naïve CD patients

02 Sep 2026 by

The effectiveness, safety, and healthcare resource utilization outcomes during the 36-month treatment period are similar across biologic-naïve patients with Crohn’s disease (CD), regardless of baseline disease location, according to a study.

Vedolizumab, ustekinumab both safe, effective in biologic-naïve CD patients

02 Sep 2026

Semaglutide works wonders in MASH, MASLD

02 Sep 2026

Use of semaglutide results in steatohepatitis resolution and improved biochemical and imaging markers among patients with metabolic dysfunction-associated steatotic liver disease (MASLD), results of a meta-analysis have shown.

Semaglutide works wonders in MASH, MASLD

02 Sep 2026

Weight loss medications rarely prescribed in patients with MASLD: study

01 Sep 2026

A survey conducted prior to resmetirom approval reports low rates of weight loss medication prescription due to low comfort potentially from lack of education despite strong beliefs that these drugs can benefit patients with metabolic dysfunction-associated steatotic liver disease (MASLD).

Weight loss medications rarely prescribed in patients with MASLD: study

01 Sep 2026

Tenofovir-sparing ART carries HBV risks

31 Aug 2026 by

Discontinuing tenofovir in antiretroviral therapy (ART) may expose people living with HIV to hepatitis B virus (HBV)-related risks, including reactivation in those previously exposed and infection in those who are susceptible, according to a systematic review and meta-analysis.

Tenofovir-sparing ART carries HBV risks

31 Aug 2026

When to resume antithrombotic therapy after GIB?

31 Aug 2026 by

Early resumption of antiplatelet therapy (APT) and anticoagulant therapy (ACT) ≤7 days after gastrointestinal bleeding (GIB) offers a favourable benefit–risk balance in patients with cardiovascular (CV) or cerebrovascular indications, according to a systematic review and meta-analysis conducted by researchers from the Chinese University of Hong Kong and Nanyang Technological University in Singapore.

When to resume antithrombotic therapy after GIB?

31 Aug 2026

Is colorectal endoscopic submucosal dissection safe in elderly patients?

30 Aug 2026

Colorectal endoscopic submucosal dissection (ESD) performed by expert endoscopists in Western older adults is safe and effective, according to a study. Outcomes are also similar to those in younger cohorts.

Is colorectal endoscopic submucosal dissection safe in elderly patients?

30 Aug 2026

Lubiprostone adjunct therapy improves bowel prep in colonoscopy

29 Aug 2026

The use of lubiprostone as an adjunct therapy for bowel preparation results in better odds of excellent quality prep, with an acceptable safety profile, a study has shown.

Lubiprostone adjunct therapy improves bowel prep in colonoscopy

29 Aug 2026

Biologic-exposed UC patients fare better with upadacitinib vs tofacitinib, ustekinumab

20 Aug 2026

In the treatment of ulcerative colitis (UC) patients with prior advanced therapy failure, subsequent treatment with upadacitinib is associated with higher remission rates compared with tofacitinib and ustekinumab, according to the retrospective TRIDENT-UC study.

Biologic-exposed UC patients fare better with upadacitinib vs tofacitinib, ustekinumab

20 Aug 2026

News & Updates

Showing Gastroenterology articles

Showing

Specialty:

1-day octreotide infusion not inferior to 5-day regimen for acute esophageal variceal bleeding

1-day octreotide infusion not inferior to 5-day regimen for acute esophageal variceal bleeding

Are PPIs necessary after endoscopic band ligation?

Are PPIs necessary after endoscopic band ligation?

Vedolizumab, ustekinumab both safe, effective in biologic-naïve CD patients

Vedolizumab, ustekinumab both safe, effective in biologic-naïve CD patients

Semaglutide works wonders in MASH, MASLD

Semaglutide works wonders in MASH, MASLD

Weight loss medications rarely prescribed in patients with MASLD: study

Weight loss medications rarely prescribed in patients with MASLD: study

Tenofovir-sparing ART carries HBV risks

Tenofovir-sparing ART carries HBV risks

When to resume antithrombotic therapy after GIB?

When to resume antithrombotic therapy after GIB?

Is colorectal endoscopic submucosal dissection safe in elderly patients?

Is colorectal endoscopic submucosal dissection safe in elderly patients?

Lubiprostone adjunct therapy improves bowel prep in colonoscopy

Lubiprostone adjunct therapy improves bowel prep in colonoscopy

Biologic-exposed UC patients fare better with upadacitinib vs tofacitinib, ustekinumab

Biologic-exposed UC patients fare better with upadacitinib vs tofacitinib, ustekinumab